vs
ALBANY INTERNATIONAL CORP（AIN）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
ALBANY INTERNATIONAL CORP的季度营收约是REPLIGEN CORP的1.6倍（$321.2M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs 4.3%，领先2.4%），REPLIGEN CORP同比增速更快（13.6% vs 12.0%），ALBANY INTERNATIONAL CORP自由现金流更多（$51.4M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 1.2%）
奥尔巴尼国际是全球先进材料与工业技术企业，下设两大核心业务板块：为造纸等工业生产提供定制工程织物的机械织物部门，以及为航空航天、国防领域研发高性能复合材料部件的工程复合材料部门，业务覆盖全球多个区域。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
AIN vs RGEN — 直观对比
营收规模更大
AIN
是对方的1.6倍
$197.9M
营收增速更快
RGEN
高出1.7%
12.0%
净利率更高
RGEN
高出2.4%
4.3%
自由现金流更多
AIN
多$33.9M
$17.6M
两年增速更快
RGEN
近两年复合增速
1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $321.2M | $197.9M |
| 净利润 | $13.9M | $13.3M |
| 毛利率 | 31.1% | 52.5% |
| 营业利润率 | 9.3% | 9.0% |
| 净利率 | 4.3% | 6.7% |
| 营收同比 | 12.0% | 13.6% |
| 净利润同比 | -21.5% | 143.9% |
| 每股收益（稀释后） | $0.56 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AINRGEN
| Q4 25 | $321.2M | $197.9M | ||
| Q3 25 | $261.4M | $188.8M | ||
| Q2 25 | $311.4M | $182.4M | ||
| Q1 25 | $288.8M | $169.2M | ||
| Q4 24 | $286.9M | $174.1M | ||
| Q3 24 | $298.4M | $154.9M | ||
| Q2 24 | $332.0M | $154.1M | ||
| Q1 24 | $313.3M | $151.3M |
净利润AINRGEN
| Q4 25 | $13.9M | $13.3M | ||
| Q3 25 | $-97.8M | $14.9M | ||
| Q2 25 | $9.2M | $14.9M | ||
| Q1 25 | $17.4M | $5.8M | ||
| Q4 24 | $17.7M | $-30.3M | ||
| Q3 24 | $18.0M | $-654.0K | ||
| Q2 24 | $24.6M | $3.3M | ||
| Q1 24 | $27.3M | $2.1M |
毛利率AINRGEN
| Q4 25 | 31.1% | 52.5% | ||
| Q3 25 | -19.1% | 53.2% | ||
| Q2 25 | 31.3% | 50.0% | ||
| Q1 25 | 33.4% | 53.6% | ||
| Q4 24 | 31.5% | 26.1% | ||
| Q3 24 | 30.3% | 50.0% | ||
| Q2 24 | 33.9% | 49.8% | ||
| Q1 24 | 34.7% | 49.5% |
营业利润率AINRGEN
| Q4 25 | 9.3% | 9.0% | ||
| Q3 25 | -44.6% | 8.9% | ||
| Q2 25 | 7.2% | 7.6% | ||
| Q1 25 | 9.8% | 3.9% | ||
| Q4 24 | 8.5% | -17.7% | ||
| Q3 24 | 8.4% | -5.1% | ||
| Q2 24 | 12.9% | 1.0% | ||
| Q1 24 | 12.4% | 1.3% |
净利率AINRGEN
| Q4 25 | 4.3% | 6.7% | ||
| Q3 25 | -37.4% | 7.9% | ||
| Q2 25 | 2.9% | 8.2% | ||
| Q1 25 | 6.0% | 3.4% | ||
| Q4 24 | 6.2% | -17.4% | ||
| Q3 24 | 6.0% | -0.4% | ||
| Q2 24 | 7.4% | 2.2% | ||
| Q1 24 | 8.7% | 1.4% |
每股收益（稀释后）AINRGEN
| Q4 25 | $0.56 | $0.24 | ||
| Q3 25 | $-3.37 | $0.26 | ||
| Q2 25 | $0.31 | $0.26 | ||
| Q1 25 | $0.56 | $0.10 | ||
| Q4 24 | $0.57 | $-0.55 | ||
| Q3 24 | $0.57 | $-0.01 | ||
| Q2 24 | $0.79 | $0.06 | ||
| Q1 24 | $0.87 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $112.3M | $767.6M |
| 总债务越低越好 | $455.7M | $542.2M |
| 股东权益账面价值 | $726.2M | $2.1B |
| 总资产 | $1.7B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.63× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资AINRGEN
| Q4 25 | $112.3M | $767.6M | ||
| Q3 25 | $108.3M | $748.7M | ||
| Q2 25 | $106.7M | $708.9M | ||
| Q1 25 | $119.4M | $697.2M | ||
| Q4 24 | $115.3M | $757.4M | ||
| Q3 24 | $127.2M | $784.0M | ||
| Q2 24 | $116.4M | $809.1M | ||
| Q1 24 | $125.4M | $780.6M |
总债务AINRGEN
| Q4 25 | $455.7M | $542.2M | ||
| Q3 25 | $480.6M | $537.9M | ||
| Q2 25 | $444.7M | — | ||
| Q1 25 | $416.4M | — | ||
| Q4 24 | $318.5M | $525.6M | ||
| Q3 24 | $362.2M | — | ||
| Q2 24 | $377.1M | — | ||
| Q1 24 | $439.1M | — |
股东权益AINRGEN
| Q4 25 | $726.2M | $2.1B | ||
| Q3 25 | $739.3M | $2.1B | ||
| Q2 25 | $888.6M | $2.1B | ||
| Q1 25 | $900.0M | $2.0B | ||
| Q4 24 | $943.5M | $2.0B | ||
| Q3 24 | $991.0M | $2.0B | ||
| Q2 24 | $967.5M | $2.0B | ||
| Q1 24 | $967.5M | $2.0B |
总资产AINRGEN
| Q4 25 | $1.7B | $2.9B | ||
| Q3 25 | $1.7B | $2.9B | ||
| Q2 25 | $1.7B | $2.9B | ||
| Q1 25 | $1.7B | $2.9B | ||
| Q4 24 | $1.6B | $2.8B | ||
| Q3 24 | $1.8B | $2.8B | ||
| Q2 24 | $1.8B | $2.9B | ||
| Q1 24 | $1.8B | $2.8B |
负债/权益比AINRGEN
| Q4 25 | 0.63× | 0.26× | ||
| Q3 25 | 0.65× | 0.26× | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.34× | 0.27× | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.39× | — | ||
| Q1 24 | 0.45× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $73.7M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $51.4M | $17.6M |
| 自由现金流率自由现金流/营收 | 16.0% | 8.9% |
| 资本支出强度资本支出/营收 | 6.9% | 4.1% |
| 现金转化率经营现金流/净利润 | 5.31× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $82.6M | $93.9M |
8季度趋势，按日历期对齐
经营现金流AINRGEN
| Q4 25 | $73.7M | $25.7M | ||
| Q3 25 | $43.9M | $48.1M | ||
| Q2 25 | $32.7M | $28.6M | ||
| Q1 25 | $2.1M | $15.0M | ||
| Q4 24 | $78.5M | $39.2M | ||
| Q3 24 | $47.0M | $49.3M | ||
| Q2 24 | $83.4M | $42.2M | ||
| Q1 24 | $9.6M | $44.7M |
自由现金流AINRGEN
| Q4 25 | $51.4M | $17.6M | ||
| Q3 25 | $25.9M | $43.4M | ||
| Q2 25 | $18.8M | $21.5M | ||
| Q1 25 | $-13.5M | $11.4M | ||
| Q4 24 | $60.2M | $33.6M | ||
| Q3 24 | $31.6M | $42.3M | ||
| Q2 24 | $63.6M | $37.4M | ||
| Q1 24 | $-17.3M | $36.4M |
自由现金流率AINRGEN
| Q4 25 | 16.0% | 8.9% | ||
| Q3 25 | 9.9% | 23.0% | ||
| Q2 25 | 6.0% | 11.8% | ||
| Q1 25 | -4.7% | 6.8% | ||
| Q4 24 | 21.0% | 19.3% | ||
| Q3 24 | 10.6% | 27.3% | ||
| Q2 24 | 19.2% | 24.3% | ||
| Q1 24 | -5.5% | 24.0% |
资本支出强度AINRGEN
| Q4 25 | 6.9% | 4.1% | ||
| Q3 25 | 6.9% | 2.5% | ||
| Q2 25 | 4.5% | 3.9% | ||
| Q1 25 | 5.4% | 2.1% | ||
| Q4 24 | 6.4% | 3.2% | ||
| Q3 24 | 5.2% | 4.5% | ||
| Q2 24 | 6.0% | 3.1% | ||
| Q1 24 | 8.6% | 5.5% |
现金转化率AINRGEN
| Q4 25 | 5.31× | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | 3.56× | 1.92× | ||
| Q1 25 | 0.12× | 2.57× | ||
| Q4 24 | 4.44× | — | ||
| Q3 24 | 2.61× | — | ||
| Q2 24 | 3.39× | 12.70× | ||
| Q1 24 | 0.35× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
RGEN
暂无分部数据
